

# High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men

Dominique L. Braun,<sup>1,2</sup> Benjamin Hampel,<sup>1,2</sup> Eileen Martin,<sup>1</sup> Roger Kouyos,<sup>1,2</sup> Katharina Kusejko,<sup>1,2</sup> Christina Grube,<sup>1</sup> Markus Flepp,<sup>3</sup> Marcel Stöckle,<sup>4</sup> Anna Conen,<sup>5</sup> Charles Béguelin,<sup>6</sup> Patrick Schmid,<sup>7</sup> Julie Delaloye,<sup>8</sup> Mathieu Rougemont,<sup>9</sup> Enos Bernasconi,<sup>10</sup> Andri Rauch,<sup>6</sup> Huldrych F. Günthard,<sup>1</sup> Jürg Böni,<sup>2</sup> and Jan S. Fehr,<sup>1,11</sup>; and the Swiss HIV Cohort Study<sup>a</sup>

<sup>1</sup>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, <sup>2</sup>Institute of Medical Virology, University of Zurich, and <sup>3</sup>Center of Infectious Diseases Zurich, <sup>4</sup>Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, <sup>5</sup>Division of Infectious Diseases and Hospital Hygiene, Cantonal Hospital Aarau, <sup>6</sup>Department of Infectious Diseases, Bern University Hospital, University of Bern, <sup>7</sup>Division of Infectious Diseases, Cantonal Hospital St Gallen, <sup>8</sup>Intensive Care Unit, Department of Intensive Care Medicine, University of Lausanne and University Hospital Center, <sup>9</sup>Division of Infectious Diseases, University Hospital Geneva, <sup>10</sup>Division of Infectious Diseases, Regional Hospital Lugano, and <sup>11</sup>Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland

**Background.** The proportion of undiagnosed hepatitis C virus (HCV) infections in high-risk populations, such as human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) is unclear. Identification of potential HCV transmitters is important to reach World Health Organization HCV elimination targets.

**Methods.** Between October 2015 and May 2016, we performed a systematic HCV RNA-based screening among HIV-infected MSM participating in the Swiss HIV Cohort Study (SHCS). HCV antibodies were measured from all HCV RNA-positive samples.

**Results.** Of 4257 MSM recorded in the SHCS database, we screened 3722 (87%) by HCV polymerase chain reaction, and 177 (4.8%) harbored a replicating HCV infection. We identified 24 individuals (14%) with incident HCV infection; one-third of them had a negative HCV antibody result at the time of HCV RNA positivity. In a multivariable model, elevated liver enzyme values (odds ratio, 14.52; 95% confidence interval, 9.92–21.26), unprotected sex with occasional partners (2.01; 1.36–2.98), intravenous drug use (7.13; 4.36–11.64), noninjectable drug use (1.94; 1.3–2.88), and previous syphilis diagnosis (2.56; 1.74–3.76) were associated with HCV RNA positivity.

**Conclusions.** A systematic HCV RNA-based screening among HIV-infected MSM revealed a high number of potential transmitters. A substantial subpopulation of MSM had incident infection, one-third of whom had a negative HCV antibody test result at the time of the HCV RNA positivity. These data reveal that one-time RNA testing of a high-risk population for HCV RNA might identify more infected persons than routine testing for HCV antibodies and liver enzymes.

**Keywords.** men who have sex with men; hepatitis C virus; HCV; HCV screening; PCR.

Since the turn of the millennium, the incidence of hepatitis C virus (HCV) infections in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) has been rising in industrialized nations [1–4]. In the Swiss HIV Cohort Study (SHCS), the proportion of MSM among patients with incident HCV infections has significantly increased, from 23% before 2006 to 85% thereafter [5, 6]. In contrast, we observed

a very strong decline in the prevalence and incidence of HCV among persons who inject drugs (PWID) in Switzerland [6] because of successful harm reduction programs since the early 1990s [7–9].

During the last 3 decades, HCV prevention efforts have ignored MSM and focused on reducing HCV transmission among PWID [10]. With the epidemiological changes in HCV transmission that have been described, HIV-infected MSM are now the key population for targeted interventions [11]. In this context, early detection of potential HCV transmitters, followed by prompt HCV treatment initiation, could be reasonable strategies to interrupt the transmission chains [12, 13]. However, the best HCV screening strategy in high-risk populations is still a matter of debate [14–16]. To date, a polymerase chain reaction (PCR)-based HCV test is the reference standard for identifying individuals with replicating disease. However, the high costs of PCR-based HCV testing limit its

Received 14 November 2017; editorial decision 24 February 2018; accepted 29 June 2018; published online August 13, 2018.

<sup>a</sup>See Acknowledgments for list of study members.

Correspondence: D. L. Braun, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland (dominique.braun@usz.ch).

Clinical Infectious Diseases® 2018;XX(XX):1–8

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciy545

implementation in clinical practice. Current guidelines recommend a HCV antibody test as the first screening test for HCV infection [17, 18]. In the case of suspected acute HCV infection (eg, unexpected elevation of liver enzyme levels), guidelines recommend HCV RNA or HCV core antigen testing as the initial evaluation [17, 18].

In the SHCS, HCV screening comprises an annual HCV antibody screening for MSM during routine clinical visits. However, using an HCV antibody test as a screening method is generating a considerable time lag, because it takes up to 6 months after HCV infection for HCV antibodies to be detected in the blood [19]. Although HCV seroconversion occurs in the majority of cases within 8 weeks when later-generation assays are used [20], a negative HCV antibody test does not reliably rule out incident HCV infection.

The Swiss HCVree Trial performed population-based systematic HCV RNA PCR testing among all MSM who participate in the SHCS and thereafter provided HCV treatment to all MSM detected with a replicating genotype 1 or 4 infection. This was in pursuit of a strategy with the primary goal of implementing an HCV elimination program at the population level. We concentrated our intervention on the MSM group, first because SHCS data suggest that HCV transmissions among PWID are almost absent [6, 21] and second because PWID with advanced liver diseases could be treated with standard of care direct-acting agents (DAAs) at the time of the study. Herein, we report on the screening period and discuss the implications of our findings for future HCV screening strategies.

## METHODS

### Swiss HCVree Trial and SHCS

The Swiss HCVree Trial is a prospective, multicenter, nationwide, interventional trial (NCT 02785666) within the SHCS consisting of 3 phases. Detailed information on the SHCS is provided in the [Supplementary Material](#) [22].

During screening period A, from 1 October 2015 to 30 June 2016, we performed systematic HCV RNA PCR-based testing among all MSM participating in the SHCS. Participants were screened at least once by HCV PCR during the 9-month screening period at one of the regular 6-monthly SHCS visits. The HCV RNA tests were paid for by Merck Sharp & Dohme. Liver enzyme (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) levels were measured at the same visit, reflecting standard-of-care SHCS procedures. In patients attending 3-monthly clinical visits, liver enzymes were measured more frequently, at 3-month intervals. HCV PCR was performed regardless of clinical suspicion for HCV infection or elevated liver enzyme levels. Detailed information on HCV testing and the costs of the HCV tests is provided in the [Supplementary Material](#).

During period B, from 1 June 2016 to 28 February 2017, HCV treatment with the once-daily combination grazoprevir-elbasvir was provided to all MSM with replicating genotype 1 or 4 infection, regardless of fibrosis stage. The study drug was provided free of charge by Merck Sharp & Dohme in the context of this investigator-initiated trial. The treatment phase was accompanied by a risk behavioral intervention for MSM who reported unprotected sex with occasional partners, with the goal of preventing reinfection after successful HCV treatment. Individuals with genotype 2 or 3 infections were treated outside the study, using standard-of-care DAAs if reimbursement requirements were fulfilled.

During the rescreening period C, from 1 March to 30 November 2017, all MSM were retested with HCV PCR to assess preintervention and postintervention prevalences in the targeted population. Local ethics committees from all participating study sites approved the study, and written consent was obtained from all participants.

### Definition of HCV Infection

Replicating HCV infection was defined as an HCV RNA result  $\geq 100$  IU/mL. We defined 3 categories for HCV infection: (1) *incident HCV infection* was defined as a negative HCV test (HCV RNA and/or anti-HCV immunoglobulin G) result documented in the SHCS database before 1 October 2015, with a positive HCV RNA result obtained thereafter; (2) *HCV reinfection* was defined as a positive anti-HCV immunoglobulin G test results but negative HCV RNA result documented in the SHCS database before October 1 2015, with a positive HCV RNA test obtained thereafter; and (3) *known HCV infection* was defined as a positive HCV test result documented in the SHCS database before 1 October 2015, with a positive HCV RNA result obtained thereafter.


### Statistical Analysis

Statistical analysis was performed using Stata software, version 15 (StataCorp). Bivariate *P* values were calculated using Fisher exact test for categorical variables and Wilcoxon or Kruskal-Wallis test for continuous variables. Univariable and multivariable logistic regression analyses were performed with the outcome of replicating HCV infection and considering covariables that were significant in the bivariate analyses at  $P < .05$ .

## RESULTS

### Study Population and Number of Replicating HCV Infections

On 1 October 2015, a total of 9128 active individuals were recorded in the SHCS database ([Figure 1](#)). Of the 4257 MSM recorded, 3722 (87%) were screened with HCV RNA PCR. Reasons for a missed HCV RNA screen ( $n = 535$ ) included dropout from the SHCS, living abroad, misclassification of MSM state in the SHCS database, death, or withdrawal of consent.



**Figure 1.** Flowchart of human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) screened for the Swiss HCVfree trial. Abbreviations: HCV, hepatitis C virus; HET, heterosexuals; IDU, intravenous drug users; SHCS, Swiss HIV Cohort Study.

Of the 3722 MSM who were screened during the study period, 177 (4.8%) harbored a replicating HCV infection. Five individuals had a HCV PCR result  $>12$  IU/mL and  $<100$  IU/mL, and 3 of them were retested with the Abbott RealTime HCV assay. Subsequent HCV PCR testing revealed a negative HCV PCR result in all individuals, so we thus considered the results at first testing as false-positive. For the remaining 2 individuals, subsequent PCR testing was not available. Genotype 1 was the most prevalent genotype ( $n = 124$ ; 70%), followed by genotypes 4 ( $n = 40$ ; 23%), 3 ( $n = 9$ ; 5%), and 2 ( $n = 2$ ; 1%). The baseline characteristics of all screened MSM stratified by replicating and nonreplicating HCV infection are shown in [Table 1](#).

#### Risk Factors for Replicating HCV Infection

Risk factors for replicating HCV infection are shown in [Table 1](#). In the multivariable analysis adjusted for all variables significantly associated with replicating HCV in [Table 1](#), elevated liver enzyme values at the time of HCV RNA positivity (odds ratio, 14.52; 95% confidence interval, 9.92–21.26), unprotected sex with occasional partners (2.01; 1.36–2.98), intravenous drug use (7.13; 4.36–11.64), noninjectable drug use (1.94; 1.3–2.88), and previous syphilis diagnosis (2.56; 1.74–3.76) were positively correlated with HCV RNA positivity ([Figure 2](#)). The receiver operating characteristic curve of risk factors from the multivariable model was 0.86.

#### Type of HCV Infection, HCV Serological Status, and Liver Enzyme Levels

Of the 177 MSM with replicating HCV, 24 (14%) had an incident HCV infection and 6 (3%) were classified as having reinfection ([Figure 1](#)). The remaining 147 MSM with replicating HCV (83%) had known HCV infections. Of the 24 MSM with an incident HCV infection, 8 (33%) had a negative HCV antibody test result at the time of the positive HCV RNA screen. The characteristics of these 8 individuals are shown in [Table 2](#). The potential delay in diagnosing HCV infection by performing standard-of-care annual HCV antibody testing was estimated by calculating the time (in days) from the first positive HCV RNA result to the time of the planned HCV serology 1 year after the last negative HCV serological result. Based on this approach, we calculated that detection of the HCV infection would have been delayed by a median of 197 days (range, 53–366 days). Fifty-four of the 177 MSM with replicating HCV infection (31%), and 4 of the 24 with incident HCV infection (17%) presented with normal liver enzyme levels at the time of the positive HCV RNA screen result. Of the 8 MSM with an incident HCV infection and a negative HCV antibody result at the time of the positive HCV RNA screen, 2 presented with normal liver enzyme values ([Table 2](#)).


#### Characteristics of Patients With Incident HCV Infection and Reinfection

Compared with MSM with a known HCV infection, those with an incident HCV infection were younger (39 vs 48 years;

**Table 1. Baseline Characteristics of 3722 Men Who Have Sex With Men Screened for Hepatitis C Virus (HCV) Infection by HCV RNA Polymerase Chain Reaction, Stratified by Replicating State**

Characteristic	No. With Data	All Participants	Replicating HCV	Nonreplicating HCV	P Value
No. of patients (%)	3722	3722 (100)	177 (4.8)	3545 (95.2)	...
Age, median (IQR), y	3715	50 (42–56)	47 (41–54)	50 (42–56)	.007
Ethnicity, No. (%)	3711				
White		3360 (90.5)	159 (89.8)	3201 (90.6)	.34
Black		60 (1.62)	6 (3.4)	54 (1.5)	
Asian		135 (3.6)	7 (4.0)	128 (3.6)	
Hispanic		152 (4.1)	5 (2.8)	147 (4.2)	
Other/unknown		4 (0.1)	0 (0.0)	4 (0.1)	
<b>HIV-related data</b>					
Time since HIV diagnosis, median (IQR), y	3715	12 (7–20)	11 (7–20)	12 (7–20)	.95
Prior AIDS, No. (%)	3538	696 (18.7)	31 (17.5)	665 (18.8)	.38
HIV viral load <50 copies/mL, No. (%)	3445	3397 (94)	156 (92.3)	3241 (94.1)	.21
CD4 cell count, median (IQR), cells/ $\mu$ L	3640	630 (480–828)	629.5 (463–778.5)	630 (480–829.5)	.22
<b>Liver-related data</b>					
ALT, median (IQR), U/L	3236	29 (22–42)	74 (42–141)	29 (21–40)	<.001
AST, median (IQR), U/L	3208	26 (22–33)	51 (33–77)	26 (21.6–31.6)	<.001
AST or ALT >50 U/L, No. (%)	3061	584 (18.0)	123 (69.5)	461 (15.1)	<.001
History of hepatitis B infection, No. (%)	3288	1503 (43.6)	78 (50.2)	1425 (43.3)	.052
<b>Other risk factors, No. (%)</b>					
Condomless sex with occasional partners	3492	932 (25.4)	83 (47.4)	849 (24.3)	<.001
Condomless sex with stable partner	3520	1235(33.4)	54 (30.7)	1181 (33.6)	.24
Intravenous drug use	3532	202(5.4)	51 (29.0)	151 (4.3)	<.001
Noninjectable drug use	3532	1145(30.8)	106 (60.2)	1039 (29.4)	<.001
Previous syphilis diagnosis	3475	1512(41.5)	106 (65.4)	1406 (40.5)	<.001
Severe alcohol consumption	2970	725 (23.3)	30 (21.9)	695 (23.4)	.39

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range.



**Figure 2.** Univariable (blue) and multivariable (red) logistic regressions for factors associated with a positive hepatitis C virus RNA screening. Abbreviations: ALT, alanine aminotransferase; AST, aspartate, aminotransferase.

$P < .001$ ), had a more recent HIV infection diagnosis (6 vs 12 years;  $P < .001$ ), and had higher ALT levels (125.5 vs 68 U/L;  $P = .009$ ) (Table 3). For the incident infections, the median time from the last negative HCV serological result recorded in the SHCS database to the time of HCV RNA positivity was 381 days (interquartile range, 259–800 days).

## DISCUSSION

In this nationwide, prospective, multicenter, interventional trial, we found that 177 of 3722 MSM from the SHCS had a replicating HCV, reflecting a prevalence of 5%. Most importantly, 14% of MSM with replicating HCV had an incident HCV infection and one-third of these patients presented with a nonreactive HCV antibody test at the time of the positive HCV RNA result.

Our finding that a substantial proportion of MSM with incident HCV infection had a negative HCV antibody result at the time of HCV RNA positivity highlights the importance of a screening approach based on a molecular test in the setting

**Table 2. Characteristics of 8 Patients With an Incident Hepatitis C Virus (HCV) Infection and a Negative HCV Antibody Test Result at the Time of Positive HCV RNA Result<sup>a</sup>**

Subject	Genotype	Date of 1st Positive HCV RNA <sup>b</sup>	Date of Last Negative HCV Antibody Test <sup>b</sup>	AST at Time of Positive HCV RNA, U/L	ALT at Time of Positive HCV RNA, U/L	Calculated Potential Delay in HCV Diagnosis, d
1	1a	22/2/2016	10/10/2015	752	1013	231
2	4	17/11/2015	12/1/2015	29	33	56
3	1a	26/10/2015	8/9/2014	32	47	366
4	1a	22/2/2016	7/10/2015	40	69	228
5	1a	21/1/2016	17/4/2015	30	53	87
6	1a	11/12/2015	11/9/2015	39	62	275
7	1a	29/7/2016	29/9/2015	663	1106	53
8	1a	17/11/2015	24/8/2015	59	89	281

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus.

<sup>a</sup>The estimated delay in diagnosing HCV infection was calculated by assessing the time (in days) from the first positive HCV RNA test result to the recommended HCV antibody test 1 year after the last negative HCV antibody test result.

<sup>b</sup>Dates presented in date/month/year format.

of a population-based HCV elimination strategy. In June 2016, the World Health Organization launched its action plan, setting the goal of eliminating viral hepatitis as a major public health threat by 2030 [23]. Aiming at preventing sexual transmission of viral hepatitis, the action plan states that specific attention

should be given to MSM with high-risk behavior. Recognizing the recently described epidemiological changes in HCV transmission among HIV-infected MSM in Switzerland, the Swiss HCV-free Trial was established to identify MSM in the SHCS with replicating infection and to treat these MSM regardless of

**Table 3. Comparison of Men Who Have Sex With Men With Replicating Hepatitis C Virus (HCV) Infection, Stratified by Incident Infection, Reinfection, or Known HCV Infection**

Characteristic	No. With Data	Incident HCV Infection	Reinfection	Known HCV Infection	P Value
No. of patients (%)	177	24 (13.6)	6 (3.4)	147 (83.1)	...
Age, median (IQR), y	177	39.5 (32–47)	40.5 (37–41)	48 (42–55)	<.001
HIV-related data					
Time since HIV diagnosis, median (IQR), y	177	6 (4–9)	6.5 (4–12)	12 (8–22)	<.001
Prior AIDS, No. (%)	177	6 (25.0)	0 (0.0)	25 (17.0)	.37
HIV viral load, <50 copies/mL, No. (%)	169	21 (91.3)	5 (83.3)	130 (92.9)	.42
CD4 cell count, median (IQR), cells/μL	172	742.5 (448–816)	660.5 (496–856)	609.5 (460–734)	.57
CD4 cell count <200 cells/μL, No. (%)	172	3 (12.5)	0 (0.0)	1 (0.7)	.02
Liver-related data					
HCV genotype, No. (%)	177				
1a		20 (83.3)	2 (33.3)	88 (59.9)	.32
1b		0 (0.0)	1 (16.7)	13 (8.8)	
2		0 (0.0)	0 (0.0)	2 (1.4)	
3		0 (0.0)	0 (0.0)	9 (6.1)	
4		4 (16.7)	3 (50.0)	33 (22.5)	
1/4 Coinfection		0 (0.0)	0 (0.0)	2 (1.4)	
HCV RNA, median (IQR), log IU/mL	177	5.78 (5.32–6.86)	5.06 (4.04–5.79)	6.00 (5.50–6.56)	.08
Anti-HCV positivity at screening, No. (%)	169	15 (62.5)	3 (50.0)	141 (95.9)	.000
Fibrosis stage at baseline (METAVIR score), No. (%)	163				
F0–F1		14 (70.0)	3 (75.0)	103 (74.1)	.68
F2		4 (20.0)	1 (25.0)	26 (18.7)	
F3		2 (10.0)	0 (0.0)	5 (3.6)	
F4		0 (0.0)	0 (0.0)	5 (3.6)	
ALT, median (IQR), U/L	177	125.5 (61.5–352.5)	188 (72–306)	68 (41–125)	.009
AST, U/L, median (IQR)	177	59 (39.5–141.5)	87 (46–141)	47 (33–71)	.04
AST or ALT >50 U/L, No. (%)	177	20 (83.3)	5 (83.3)	98 (66.7)	.23
Previous HCV treatment, No. (%)	174	0 (0.0)	31 (21.5)	1 (16.7)	.02

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range.

reimbursement restrictions, with the goal of rapidly reducing the pool of potential transmitters.

The HCV prevalence of 5% assessed in our HIV-infected population is remarkably high. A study performed in 2010 in Zurich, Switzerland, found a HCV seroprevalence of 0.37% among 821 HIV-uninfected MSM, only 1 of whom harbored replicating virus [24]. For the HIV-infected MSM population in Switzerland, the point prevalence of replicating HCV has not been systematically determined so far. Wandeler et al [6, 25] assessed the number of HCV infections among HIV-infected MSM in the SHCS from 1998 to 2011 and found that 147 of 4629 MSM (3.2%) had a positive HCV serological result at the time of study entry. However, some of them had been treated in the meantime or experienced spontaneous clearance, and therefore these data do not reflect the current prevalence of replicating HCV infection. The unique setting of the SHCS combined with our systematic HCV RNA screening allowed us for the first time to determine exact HCV prevalence and incidence data in the HIV-infected Swiss MSM community.

With our systematic HCV RNA-based screening, we tested almost 4000 HIV-infected MSM for HCV. One of the key questions regarding such an approach is whether this truly reflects the population at risk or if HIV-uninfected MSM should also be included in a systematic HCV screening program. There is evidence from literature that the HCV epidemic is concentrated among HIV-infected MSM [4, 26]. However, a recent study from Amsterdam that tested high-risk HIV-uninfected MSM for HCV by HCV antibodies and HCV RNA found a similar HCV prevalence of 4.8% [27]. Given the heterogeneous risk profile of MSM for HCV, and the high costs of HCV RNA-based screening programs, a screening algorithm based on individual risk factors could be a reasonable strategy for the future.

A risk-based HCV RNA screening approach should be based on factors that are independently associated with a positive HCV RNA screen. Most of these risk factors we have found to be a proxy for high-risk transmission behavior and have been associated with a higher risk for HCV acquisition in previous studies [21, 28–31]. They can be easily assessed within a short time and could guide the clinician to opt for an HCV PCR test instead of the usual HCV antibody screening. That a risk factor-based screening approach might be useful in finding new HCV diagnoses has been previously shown in other settings, for example, among PWID.

In a study by Kim et al [32], newly incarcerated inmates were screened for acute HCV infection by using a simple screening questionnaire and an AST threshold >7 times the upper limit of normal. With this risk-based screening, the authors identified 1 case of acute HCV infection per 100 persons screened. However, in the setting of an AST-based screening approach, one must remember that the absence of liver enzyme elevation does not rule out an HCV infection; one-third of the MSM with a positive HCV RNA test result did not have elevated liver

enzyme level in our study at the time of the positive screen. On the other hand, elevated liver enzyme levels should prompt physicians to perform an HCV RNA test in individuals at high risk for HCV acquisition. The fact that in our study 15% of the MSM with a negative HCV RNA result nevertheless had elevated liver enzyme levels—defined as an AST or ALT level >50 U/L—reflects the high burden of liver disease and other comorbid conditions in HIV-infected individuals and emphasizes the need for a careful clinical assessment of elevated liver enzyme levels in this patient population [33]. The proportion of HCV RNA-negative MSM with elevated liver enzyme levels would even increase to 50% with an ALT cutoff of >30 U/L.

Our systematic HCV RNA-based screening approach identified a substantial proportion of MSM with an incident HCV infection. Remarkably, in our study one-third of patients with an incident HCV infection had a negative HCV antibody test result despite HCV replication. We calculated a median delay of 197 days (range, 53–366 days) in the diagnosis of incident HCV infection when following the SHCS standard-of-care annual HCV antibody testing. In the context of an elimination program, this delay could be relevant, because a timely diagnosis without gaps is paramount to following the principle of “treatment as prevention.” The impact of this delay also depends on the fraction of transmission events during early infection phases. Although this is not known for HCV, detailed analyses of HIV suggest that early infection phases may play a crucial role for transmission and thus also for elimination [34].

One can argue that all but 2 of the MSM with an incident HCV infection would have been identified combining HCV serology as the initial screen with subsequent HCV RNA testing in case of a negative serological result with elevated liver enzyme levels. However, this strategy would also generate a high number of PCR tests because of the high proportion of HIV-infected individuals with elevated liver enzymes. In addition, it would be logistically challenging, because the patient had to attend the clinic twice for the subsequent HCV PCR test. Because the cost of HCV PCR in our elimination study were similar to that of a commercially available HCV antibody test, a stepwise testing approach would have generated even higher costs than systematic PCR-based screening. Such low prices for HCV PCR are negotiable if big test volumes are used for population wide programs for example, for elimination programs.

Our study had several strengths. The study population is very representative of the HIV-infected MSM community living in Switzerland; models estimate that about 75% of all HIV-infected MSM living in Switzerland participate in the SHCS [35]. Because we used a very sensitive PCR assay for HCV screening, a negative test result could reliably rule out replicating HCV in the tested individual. As a limitation, we cannot rule out the possibility that we missed an HCV infection that occurred after the negative screening and HCV transmission events, which affected non-SHCS participants. In addition, because the

natural history of HCV infection can be characterized by HCV RNA negativity and subsequent clearance but also by recurrence of viremia after alleged clearance [36], we might missed such cases. However, given that all MSM were rescreened during period C, this probability is rather low. Another limitation is that our systematic HCV screening approach leads to an unnecessary screening of MSM with a very low risk for HCV and was associated with substantial costs, but this strategy was essential to identify risk factors. Finally, contamination of specimens or borderline results may have led to misinterpretation of the test results, leaving the participants with some unease.

In conclusion, our study findings have several important implications for reaching the World Health Organization targets of a 90% reduction in new HCV cases by 2030. First, in the context of a HCV elimination strategy, HCV RNA-based screening should be considered in sexually active MSM, particularly when they report the above-mentioned risk factors. The strategy of using HCV PCR to screen high-risk MSM with signs of acute HCV infection is also recommended by international guidelines [37]. This is because delayed diagnosis and therapy substantially increase the time individuals spend with replicating HCV infection and therefore the probability of their transmitting the infection to other sex partners. A test for HCV core antigen as a surrogate marker of HCV replication can be performed when HCV RNA tests are not available or not affordable [17]. Second, we recommend PCR-based screening in patients with successfully treated or self-cleared HCV infections. This is for timely identification of reinfection and/or relapse. Third, batch-wise HCV RNA screening is encouraged in order to lower costs. Finally, consultations should be used to promote safer sex practices, because suppressive antiretroviral therapy does not replace condoms for protection from HCV and other sexually transmitted infections in general.

### Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

### Notes

**Author contributions.** D. L. B., A. R., J. B., and J. S. F. designed the study. D. L. B., B. H., C. G., M. F., M. S., A. C., C. B., P. S., J. D., M. R., E. B., and J. B. acquired the data. R. K. and K. K. performed statistical analysis. D. L. B., J. B., and J. S. F. supervised the study. D. L. B. wrote the first draft of the manuscript. All investigators contributed to data collection and interpretation, reviewed drafts of the manuscript, and approved the final manuscript.

**Acknowledgments.** We are grateful to all patients who participated in the study. We thank all Swiss HIV Cohort Study (SHCS)-affiliated private physicians and all study nurses for their dedicated patient work. We also thank all clinical and laboratory staff at the different SHCS sites who have contributed to this study. We acknowledge Erik Mossdorf, Silvana Renner, Daniele Viviani, and the team from Merck Sharp & Dohme for supporting the study. We thank the Institute for Medical Virology from the University of Zurich, particularly Alice Krause, Sarah Wicki, Ruth Hefti, Verena

Anukege, and Nancy Kurmann, and all SHCS-affiliated laboratories for their excellent laboratory work; Maja Müller and Alexandra Matter from the Clinical Trials Center Zurich for careful study monitoring; and Danièle Perraudin and Mirjam Minichiello from the SHCS coordination center for their assistance.

**Disclaimer.** The opinions expressed in this article are those of the authors and do not necessarily represent those of Merck Sharp & Dohme. Merck Sharp & Dohme had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Financial support.** This study was supported by Merck Sharp & Dohme (research grant from its Investigator-Initiated Studies Program), the Swiss National Science Foundation (grants 33CS30-148522 and 324730-112594 to the SHCS and grants PZ00P3-142411 and BSSGIO\_155851 to R. K.), SHCS project 772 (support for this work and the SHCS research foundation), and the University of Zurich's Clinical Research Priority Program Zurich Primary HIV Infection Study (D. L. B., B. H., and H. F. G.).

**SHCS members.** A. Anagnostopoulos, M. Battegay, E. B., J. B., D. L. B., H. C. Bucher, A. Calmy, M. Cavassini, A. Ciuffi, G. Dollenmaier, M. Egger, L. Elzi, J. S. F., J. Fellay, H. Furrer (chairman of the Clinical and Laboratory Committee), C. A. Fux, H. F. G. (president of the SHCS), D. Haerry (deputy of the "Positive Council"), B. Hasse, H. H. Hirsch, M. Hoffmann, I. Hösli, M. Huber, C. Kahlert, L. Kaiser, O. Keiser, T. Klimkait, R. K., H. Kovari, B. Ledergerber, G. Martinetti, B. Martinez de Tejada, C. Marzolini, K. J. Metzner, N. Müller, D. Nicca, P. Paioni, G. Pantaleo, M. Perreau, A. R. (chairman of the Scientific Board), C. Rudin (chairman of the Mother & Child Substudy), A. U. Scherrer (data center head), P. S., R. Speck, M. S., P. Tarr, A. Trkola, P. Vernazza, G. Wandeler, R. Weber, and S. Yerly.

**Potential conflicts of interest.** All authors: No reported conflicts of Interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

### References

1. Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001–2009. *Euro Surveill* 2010; 15:19673.
2. Sánchez C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. *Liver Int* 2013; 33:1357–62.
3. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. *AIDS* 2010; 24:1799–812.
4. Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. *Sex Transm Infect* 2012; 88:558–64.
5. Rauch A, Rickenbach M, Weber R, et al; Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. *Clin Infect Dis* 2005; 41:395–402.
6. Wandeler G, Gsponer T, Bregenzer A, et al; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. *Clin Infect Dis* 2012; 55:1408–16.
7. Nordt C, Stohler R. Combined effects of law enforcement and substitution treatment on heroin mortality. *Drug Alcohol Rev* 2010; 29:540–5.
8. Locicero S, Gervasoni JP, Jeannin A, Dubois-Arber F. Survey of drug users, clients of low-threshold facilities (SBS) in Switzerland. 1993–2011 trends. Lausanne, Switzerland: University Institute for Social and Preventive Medicine, 2013.
9. Bruggmann P, Blach S, Deltenre P, et al. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. *Swiss Med Wkly* 2017; 147:w14543.
10. Hagan LM, Schinazi RF. Best strategies for global HCV eradication. *Liver Int* 2013; 33(suppl 1):68–79.
11. Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. *Trends Microbiol* 2013; 21:625–33.
12. Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. *Lancet Gastroenterol Hepatol* 2016; 1:317–27.
13. Ghany MC. IDSA and AASLD guidelines on recommendations for testing, managing, and treating Hepatitis C: management of acute HCV Infection. Last update 21 September 2017. Available at: [www.hcvguidelines.org/](http://www.hcvguidelines.org/). Accessed 18 January 2018.

14. Assoumou SA, Tasillo A, Leff JA, et al. Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings. *Clin Infect Dis* **2018**; 66:376–84.
15. Samandari T, Tedaldi E, Armon C, et al. Incidence of hepatitis C virus infection in the human immunodeficiency virus outpatient study cohort, 2000–2013. *Open Forum Infect Dis* **2017**; 4:ofx076.
16. van Rooijen M, Heijman T, de Vrieze N, et al. Earlier detection of hepatitis C Virus infection through routine hepatitis C virus antibody screening of human immunodeficiency virus-positive men who have sex with men attending a sexually transmitted infection outpatient clinic: a longitudinal study. *Sex Transm Dis* **2016**; 43:560–5.
17. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. *J Hepatol* **2017**; 66:153–94.
18. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology* **2015**; 62:932–54.
19. Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. *AIDS* **2009**; 23:89–93.
20. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. *Vox Sang* **1995**; 68:15–8.
21. Wandeler G, Schlauri M, Jaquier ME, et al. Incident hepatitis C virus infections in the Swiss HIV Cohort Study: changes in treatment uptake and outcomes between 1991 and 2013. *Open Forum Infect Dis* **2015**; 2:ofv026.
22. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. *Int J Epidemiol* **2010**; 39:1179–89.
23. World Health Organization. Action plan for the health sector response to viral hepatitis in the WHO European Region. 2017. World Health Organization Regional Office for Europe. Available at: [http://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0008/357236/Hepatitis-9789289052870-eng.pdf](http://www.euro.who.int/__data/assets/pdf_file/0008/357236/Hepatitis-9789289052870-eng.pdf). Accessed 17 July 2018.
24. Schmidt AJ, Falcató L, Zahno B, et al. Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? *BMC Public Health* **2014**; 14:3.
25. Wandeler G, Dufour JF, Bruggmann P, Rauch A. Hepatitis C: a changing epidemic. *Swiss Med Wkly* **2015**; 145:w14093.
26. Ghisla V, Scherrer AU, Nicca D, Braun DL, Fehr JS. Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000–2016: a systematic review and meta-analysis. *Infection* **2017**; 45:309–21.
27. Hoornborg E, Achterbergh RCA, Schim Van Der Loeff MF, et al. Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. *AIDS* **2017**.
28. Matthews GV, Pham ST, Hellard M, et al; ATAHG Study Group. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. *Clin Infect Dis* **2011**; 52:803–11.
29. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology* **2009**; 136:1609–17.
30. Chow EP, Lau JT, Zhuang X, Zhang X, Wang Y, Zhang L. HIV prevalence trends, risky behaviours, and governmental and community responses to the epidemic among men who have sex with men in China. *Biomed Res Int* **2014**; 2014:607261.
31. Vanhommerig JW, Lambers FA, Schinkel J, et al. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. *Open Forum Infect Dis* **2015**; 2:ofv115.
32. Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users. *Hepatology* **2013**; 57:944–52.
33. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. *Clin Infect Dis* **2010**; 50:502–11.
34. Marzel A, Shilahi M, Yang WL, et al; Swiss HIV Cohort Study. HIV-1 transmission during recent infection and during treatment interruptions as major drivers of new infections in the Swiss HIV Cohort Study. *Clin Infect Dis* **2016**; 62:115–22.
35. Nordt C, Gebhardt M, Stohler R, Weber R; Swiss HIV Cohort Study. A medical care career approach to model HIV/AIDS incidence and prevalence in Switzerland 1980–2010: combining cohort and surveillance data. Presented at: 13th European AIDS Conference (EACS 2011); 12–15 October 2011; Belgrade, Serbia. Abstract PS8/3.
36. Mosley JW, Operskalski EA, Tobler LH, et al; Transfusion-transmitted Viruses Study and Retrovirus Epidemiology Donor Study Groups. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. *J Viral Hepat* **2008**; 15:120–8.
37. European AIDS Clinical Society. EACS guidelines version 9.0. Algorithm for management of acute HCV in persons with HCV/HIV co-infection. **2017**. Available at: [www.eacsociety.org/files/guidelines\\_9.0-english.pdf](http://www.eacsociety.org/files/guidelines_9.0-english.pdf). Accessed 17 July 2018.